Amylyx Pharmaceuticals Raises $500M in Upsized Stock Offering
Event summary
- Amylyx priced a $500M upsized public offering of 14.09M shares at $35.50 per share.
- Underwriters have a 30-day option to purchase an additional 2.11M shares.
- Proceeds will fund pre-commercial activities for avexitide, R&D, and working capital.
- Offering expected to close on August 21, 2026.
The big picture
Amylyx's $500M offering underscores the biotech sector's reliance on public markets to fund late-stage drug development. The upsizing suggests robust demand for rare disease therapies, particularly as avexitide nears potential commercialization. The move also highlights the competitive landscape for neurodegenerative and endocrine treatments, where Amylyx is positioning itself as a key player.
What we're watching
- Execution Risk
- How Amylyx will deploy the $500M to advance avexitide and other pipeline candidates.
- Market Dynamics
- Whether the upsized offering reflects strong investor confidence in Amylyx's pipeline.
- Strategic Focus
- The pace at which Amylyx can secure additional manufacturing capacity for avexitide.
Related topics